OxyContin maker bows out of meeting on harder-to-abuse drug

WASHINGTON (AP) – The makers of the potent painkiller OxyContin have pulled out of a federal meeting scheduled for next week to review the company’s harder-to-abuse version of the much-debated drug.

An executive for Purdue Pharma says the company wants more time to review and analyze its data. As a result, the company has withdrawn its application that was slated to be reviewed before a Food and Drug Administration committee next week.

FDA meetings are typically planned months in advance and cancellations are highly unusual.

OxyContin – which has long been associated with risks of addiction and overdose – is formulated to discourage patients from crushing the tablets for snorting or injection. Next week’s meeting was intended to evaluate whether those features actually translate into reduced rates of abuse by chronic pain patients.

(Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s